Vnitr Lek 2026, 72(6):364-372 | DOI: 10.36290/vnl.2026.069

The role of SGLT2 inhibitors in outpatient cardiology practice

Petra Buděšínská
Kardiocentrum, Nemocnice Karlovy Vary

The article discusses the beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors (gliflozins) on the kidneys and the heart, thereby slowing the progression of pathophysiological processes underlying heart failure and chronic kidney disease, which may ultimately lead to cardiorenal syndrome. Early diagnosis of these processes through interdisciplinary cooperation among internal medicine specialties, with a focus on biomarkers of heart failure and renal impairment, including NT-proBNP, eGFR, and albuminuria, enables timely initiation of treatment with these drugs.

Keywords: chronic kidney disease, heart failure with preserved ejection fraction, sodium-glucose cotransporter 2 inhibitors, cardiovascular prevention, NT-proBNP, albuminuria.

Accepted: September 15, 2026; Published: October 2, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Buděšínská P. The role of SGLT2 inhibitors in outpatient cardiology practice. Vnitr Lek. 2026;72(6):364-372. doi: 10.36290/vnl.2026.069.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pudil R. Srdeční selhání. 2. vyd. Praha: Maxdorf 2023: 168. ISBN 978-80-7345-756-3.
    2. Malík J, et al. Echokardiografie u pacientů s chronickým onemocněním ledvin a úvod do kardionefrologie. Maxdorf: Czech Republic 2018:35. ISBN 978-80-7345-566-8.
    3. Hegarová M, et al. Kardiorenální syndrom v kontextu srdečního selhání a inhibitory SGLT2. Acta medicinae. 2025;14(1-2):27.
    4. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of medicine. 2020;383(15):1437. Go to original source...
    5. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England Journal of medicine. 2019;380(4):350. Go to original source...
    6. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. The New England Journal of medicine. 2019;381(21):1995. Go to original source... Go to PubMed...
    7. Solomon SD, McMurray JJV, Anand IS, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. The New England Journal of medicine. 2022; 387(12):1089. Go to original source... Go to PubMed...
    8. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. The New England Journal of medicine. 2020;383(15):1440. Go to original source...
    9. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of medicine. 2015;373(22):2120. Go to original source...
    10. Packer M, Anker SD, Butler J, et al. Empagliflozin in patients with heart failure and reduced ejection fraction. The New England Journal of medicine. 2020;383(15):1413. Go to original source... Go to PubMed...
    11. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. The New England Journal of medicine. 2021;385(16):1451. Go to original source... Go to PubMed...
    12. Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. The New England Journal of medicine. 2023;388(2):117. Go to original source... Go to PubMed...
    13. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. The New England Journal of medicine. 2021;384(2):118. Go to original source...
    14. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. The New England Journal of medicine. 2021;384(2):129. Go to original source... Go to PubMed...
    15. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. The New England Journal of medicine. 2017;377(7):647. Go to original source...
    16. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. The New England Journal of medicine. 2020;383(15):1425. Go to original source...
    17. Dyck JRB, et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. JMCC. 2022;165:27. Go to original source...
    18. Potter LR. Natriuretic Peptides: Their Structures, Receptors, Physiologic Functions and Therapeutic Applications. In: Schmidt HH, Stasch JP, Hofmann F (eds). cGMP: Generators, Effectors and Therapeutic Implications. Berlin: Springer 2009: 191,352. Go to original source...
    19. Jhund PS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine. 2022;28(9):1957. Go to original source... Go to PubMed...
    20. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. The New England Journal of medicine. 2019;380(24):2295. Go to original source...
    21. Khan MS, et al. Albuminuria and Heart Failure: JACC State-of-the-Art review. Journal of the American College of Cardiology. 2023;81(3):270. Go to original source...
    22. Anderson L, et al. Suspected de novo heart failure in outpatient care: The REVOLUTION HF study. The European Heart Journal. 2025;46(19):1502. Go to original source... Go to PubMed...
    23. Lund LH, et al. Healthcare utilization and costs in patients with new-onset heart failure: the REVOLUTION study. The European Heart Journal. 2025;46(19):1493.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.